Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.

Autor: Ouahoud S; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., Jacobs RJ; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., Kodach LL; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., Voorneveld PW; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., Hawinkels LJAC; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., Weil NL; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., van Vliet B; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., Herings RM; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.; Department of Epidemiology & Data Science, Utrecht, The Netherlands., van der Burg LRA; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands., van Wezel T; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Morreau H; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Slingerland M; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Bastiaannet E; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.; Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands., Putter H; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands., Hardwick JCH; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Utrecht, The Netherlands. j.c.h.hardwick@lumc.nl.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2022 Feb; Vol. 126 (2), pp. 297-301. Date of Electronic Publication: 2021 Oct 26.
DOI: 10.1038/s41416-021-01604-6
Abstrakt: Background: Long-term use of statins is associated with a small reduced risk of colorectal cancer but their mechanism of action is not well understood. While they are generally believed to act on KRAS, we have previously proposed that they act via influencing the BMP pathway. The objective of this study was to look for associations between statin use and the risk of developing colorectal cancer of a particular molecular subtype.
Methods: By linking two registries unique to the Netherlands, 69,272 statin users and 94,753 controls were identified and, if they developed colorectal cancer, their specimens traced. Colorectal cancers were molecularly subtyped according to the expression of SMAD4 and the mutation status of KRAS and BRAF.
Results: Statin use was associated with a reduction in the risk of developing colorectal cancer regardless of molecular subtype (HR 0.77; 95% CI 0.66-0.89) and a larger reduction in the risk of developing SMAD4-positive colorectal cancer (OR 0.64; 95% CI 0.42-0.82). There was no relationship between statin use and the risk of developing colorectal cancer with a mutation in KRAS and/or BRAF.
Conclusions: Statin use is associated with a reduced risk of developing colorectal cancer with intact SMAD4 expression.
(© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: